Lloyd Properties donates 860 acres of Ventura hillsides to land trust
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen spends big to defeat Proposition 61
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen sells Colorado facility to AstraZeneca for $64.5 million
Thousand Oaks biotech giant Amgen continued its Colorado exit plans recently as it sold a Longmont, Colo., facility to London-based pharmaceutical and biotech company AstraZeneca for $64.5 million. Amgen built the 692,000-square-foot facility in the 1990s to make ingredients for its blockbuster anti-anemia drug Epogen. The site used large vats to produce lines of cell Read More →
Read More →VC housing projects can’t compete for state funds
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Thousand Oaks apartment complex sells for $67 million
A 191-unit multifamily community at 491 W. Gainsborough Road in Thousand Oaks sold for $67 million. Pacific Urban Residential bought the property from IMT Capital LLC, according to Greg Harris of Marcus & Millichap who coordinated the deal. “The acquisition provided the buyer with the opportunity to enter a highly coveted market supported by the Read More →
Read More →Amgen partners with Swedish company to develop drugs
Thousand Oaks-based Amgen will pay a Swedish company up to $410 million to help it develop oncology and neuroscience drugs. The companies announced the partnership Oct. 4 and said Nuevolution will use its Chemetics drug discovery platform to discover drugs for Amgen. Nuevolution may receive licensing payments along with development, commercial and milestone payments. It Read More →
Read More →Amgen leukemia drug cures 39 percent of treated patients, study finds
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
